Naomi Fujioka

Dr. Naomi Fujioka

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2020 in Cancers
Verified
Journal Article
Open access
PDF file
Daniel ValleraDaniel Vallera
Daniel Vallera
Soldano FerroneSoldano Ferrone
Soldano Ferrone
BKBehiye Kodal
Behiye Kodal
PHPeter Hinderlie
Peter Hinderlie
LBLaura Bendzick
Laura Bendzick
MFMartin Felices
Martin Felices
We improved the bispecific antibody platform that primarily engages natural killer (NK) cells to kill cancer cells through antibody-dependent cellular cytotoxicity (ADCC) by adding IL-15 as a crosslinker that expands and self-sustains the effector NK cell population. The overall goal was to target B7-H3, an established marker predominantly expressed on cancer cells and minimally expressed on normal cells, and prove that it could target cancer cells in vitro and inhibit tumor growth in vivo. The tri-specific killer engager (TriKETM) was assembled by DNA shuffling and ligation using DNA encoding a camelid anti-CD16 antibody fragment, a wild-type IL-15 moiety, and an anti-B7-H3 scFv (clone 376.96). The expressed and purified cam1615B7H3 protein was tested for in vitro NK cell activity against a variety of tumors and in vivo against a tagged human MA-148 ovarian cancer cell line grafted in NSG mice. cam1615B7H3 showed specific NK cell expansion, high killing activity across a range of B7-H3+ carcinomas, and the ability to mediate growth inhibition of aggressive ovarian cancer in vivo. cam1615B7H3 TriKE improves NK cell function, expansion, targeted cytotoxicity against various types of B7-H3-positive human cancer cell lines, and delivers an anti-cancer effect in vivo in a solid tumor setting.

1 February 2014 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
NFNaomi Fujioka
Naomi Fujioka
CACheryl E. Ainslie-Waldman
Cheryl E. Ainslie-Waldman
PUPramod Upadhyaya
Pramod Upadhyaya
SCSteven G. Carmella
Steven G. Carmella
VFVincent A. Fritz
Vincent A. Fritz
SHStephen S. Hecht
Stephen S. Hecht
Background: Brassica vegetable consumption may confer a protective effect against cancer, possibly attributable to their glucosinolates. Glucobrassicin is a predominant glucosinolate and is the precursor of indole-3-carbinol (I3C), a compound with anticancer effects. However, objective assessments of I3C uptake from Brassica vegetables have not been successful. Methods: We conducted a randomized, crossover trial to test whether 3,3′-diindolylmethane (DIM, a metabolite of I3C) excreted in the urine after consumption of raw Brassica vegetables with divergent glucobrassicin concentrations is a marker of I3C uptake from such foods. Twenty-five subjects were fed 50 g of either raw “Jade Cross” Brussels sprouts (high glucobrassicin concentration) or “Blue Dynasty” cabbage (low glucobrassicin concentration) once daily for 3 days. All urine was collected for 24 hours after vegetable consumption each day. After a washout period, subjects crossed over to the alternate vegetable. Urinary DIM was measured using a novel liquid chromatography-electrospray ionization-tandem mass spectrometry–selected reaction monitoring (LC-ESI-MS/MS-SRM) method with [2H2]DIM as internal standard. Results: Urinary DIM was consistently and significantly higher after Brussels sprouts feeding than after cabbage feeding, as evidenced by an average difference of 8.73 pmol/mg creatinine (95% confidence interval, 5.36–12.10; P = 0.00002). Conclusion: We have successfully quantified urinary DIM after uptake of I3C from food, and demonstrated that differences in glucobrassicin exposure are reflected in urinary DIM levels. Impact: Our LC-ESI-MS/MS-SRM method and the results of our study indicate urinary DIM is a measure of I3C uptake from Brassica vegetables, a finding that can be utilized in prospective epidemiologic and chemoprevention studies. Cancer Epidemiol Biomarkers Prev; 23(2); 282–7. ©2013 AACR.

1 October 2016 in Cancer Prevention Research
Verified
Journal Article
Open access
PDF file
NFNaomi Fujioka
Naomi Fujioka
BRBenjamin W. Ransom
Benjamin W. Ransom
SCSteven G. Carmella
Steven G. Carmella
PUPramod Upadhyaya
Pramod Upadhyaya
BLBruce R. Lindgren
Bruce R. Lindgren
SHStephen S. Hecht
Stephen S. Hecht
Glucobrassicin in Brassica vegetables gives rise to indole-3-carbinol (I3C), a compound with potent anticancer effects in preclinical models. We previously showed that the urinary metabolite 3,3′-diindolylmethane (DIM) could discriminate between volunteers fed high and low doses of Brassica vegetables. However, the quantitative relationship between glucobrassicin exposure and urinary DIM level is unclear. We conducted a clinical trial to examine the hypotheses that a range of glucobrassicin exposure from Brassica vegetables is reflected in urinary DIM and that this effect plateaus. Forty-five subjects consumed vegetables, a mixture of brussels sprouts and/or cabbage, at one of seven discrete dose levels of glucobrassicin ranging from 25 to 500 μmol, once daily for 2 consecutive days. All urine was collected for 24 hours after each vegetable-eating session. Urinary DIM was measured using our published liquid chromatography-electrospray ionization-tandem mass spectrometry-selected reaction monitoring (LC/ESI-MS/MS-SRM) method. Urinary DIM excretion increased predictably with increasing glucobrassicin dose and plateaued between 200 and 300 μmol of glucobrassicin. The association between glucobrassicin dose and urinary DIM was strong and positive (R2 = 0.68). The majority of DIM was excreted in the first 12 hours after vegetable consumption. We conclude that urinary DIM is a reliable biomarker of glucobrassicin exposure and I3C uptake and that feeding glucobrassicin beyond 200 μmol did not consistently lead to more urinary DIM, suggesting a plateau in potential chemopreventive benefit. Cancer Prev Res; 9(10); 788–93. ©2016 AACR.

26 February 2020 in Cancer Prevention Research
Verified
Journal Article
Open access
PDF file
YWYi Wang
Yi Wang
SNSreekanth C. Narayanapillai
Sreekanth C. Narayanapillai
KTKatelyn M. Tessier
Katelyn M. Tessier
LSLori G. Strayer
Lori G. Strayer
PUPramod Upadhyaya
Pramod Upadhyaya
CXCheng-Guo Xing
Cheng-Guo Xing
Tobacco smoking is the primary risk factor for lung cancer, driven by the addictive nature of nicotine and the indisputable carcinogenicity of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) as well as other compounds. The integration of lung cancer chemoprevention with smoking cessation is one potential approach to reduce this risk and mitigate lung cancer mortality. Experimental data from our group suggest that kava, commonly consumed in the South Pacific Islands as a beverage to promote relaxation, may reduce lung cancer risk by enhancing NNK detoxification and reducing NNK-derived DNA damage. Building upon these observations, we conducted a pilot clinical trial to evaluate the effects of a 7-day course of kava on NNK metabolism in active smokers. The primary objective was to compare urinary total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL plus its glucuronides, major metabolites of NNK) before and after kava administration as an indicator of NNK detoxification. Secondary objectives included determining kava's safety, its effects on DNA damage, tobacco use, and cortisol (a biomarker of stress). Kava increased urinary excretion of total NNAL and reduced urinary 3-methyladenine in participants, suggestive of its ability to reduce the carcinogenicity of NNK. Kava also reduced urinary total nicotine equivalents, indicative of its potential to facilitate tobacco cessation. Plasma cortisol and urinary total cortisol equivalents were reduced upon kava use, which may contribute to reductions in tobacco use. These results demonstrate the potential of kava intake to reduce lung cancer risk among smokers.

1 September 2020 in Journal of Geriatric Oncology
Verified
Journal Article
Closed access
SMSchelomo Marmor
Schelomo Marmor
SCSeth Cohen
Seth Cohen
NFNaomi Fujioka
Naomi Fujioka
LCL. Chinsoo Cho
L. Chinsoo Cho
ABAmit Bhargava
Amit Bhargava
SMStephanie Misono
Stephanie Misono

Verified
Journal Article
Open access
PDF file
LYLiBang Yang
LiBang Yang
AGAdam Gilbertsen
Adam Gilbertsen
BJBlake Jacobson
Blake Jacobson
JPJenny Pham
Jenny Pham
NFNaomi Fujioka
Naomi Fujioka
Robert KratzkeRobert Kratzke
Robert Kratzke
Cancer markers are measurable molecules in the blood or tissue that are produced by tumor cells or immune cells in response to cancer progression. They play an important role in clinical diagnosis, prognosis, and anti-drug monitoring. Although DNA, RNA, and even physical images have been used, proteins continue to be the most common marker. There are currently no specific markers for lung cancer. Metastatic lung cancer, particularly non-small-cell lung cancer (NSCLC), is one of the most common causes of death. SFPQ, YY1, RTN4, RICTOR, LARP6, and HELLS are expressed at higher levels in cells from NSCLC than in control or cells from inflammatory diseases. SFPQ shows the most difference between the three cell types. Furthermore, the cytoplasmic isoform of SFPQ is only found in advanced cancers. We have developed ELISAs to detect SFPQ and the long and short isoforms. Evidence has shown that the short isoform exists primarily in cancers. Furthermore, immunocytometry studies and IHC analysis have revealed that SFPQ levels are consistent with ELISA results. In addition, enhanced DNA methylation in the SFPQ gene may facilitate the SFPQ expression differences between control and cancer cells. Considering this, elevated SFPQ level and the isoform location could serve as a cancer diagnostic and prognostic marker.